The antiemetic effect of granisetron in lower hemibody radiotherapy.
AffiliationDepartment of Radiotherapy and Oncology, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractRadiotherapy-induced emesis is poorly controlled with existing antiemetics. 5-Hydroxytryptamine (5HT3) receptor antagonists are a new class of antiemetics which have been demonstrated to be effective in controlling cytotoxic-induced emesis. We have prospectively studied the antiemetic efficacy of the 5HT3 receptor antagonist granisetron in an open non-randomized efficacy and toxicity study, at two dose levels, in patients receiving lower hemibody radiotherapy for multiple bone metastases. Of the 22 patients studied, 13 patients received 20 micrograms/kg and nine patients 40 micrograms/kg of granisetron, administered as an intravenous infusion 1 h before radiotherapy. Radiotherapy was administered as a single exposure to the lower half body to a midline dose of 8 Gy. A complete response (no nausea or vomiting) was observed in 9/13 patients at the lower dose level and 6/9 patients at the higher level. No major adverse events were recorded. We conclude that granisetron is a well-tolerated and effective antiemetic agent in radiotherapy-induced emesis. Formal comparison with conventional antiemetic agents in this situation is required.
CitationThe antiemetic effect of granisetron in lower hemibody radiotherapy. 1991, 3 (5):247-9 Clin Oncol
- Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis.
- Authors: Belkacémi Y, Ozsahin M, Pène F, Rio B, Sutton L, Laporte JP, Touboul E, Gorin NC, Laugier A
- Issue date: 1996 Aug 1
- Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
- Authors: Addelman M, Erlichman C, Fine S, Warr D, Murray C
- Issue date: 1990 Feb
- Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
- Authors: Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C
- Issue date: 1998 Jan-Feb
- [The use of granisetron per os in radiotherapy-induced emesis].
- Authors: Krengli M, Lazzari R, Manara M
- Issue date: 1996 Dec